Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In The News: New Top Leadership At Incyte, USP; Former CMS Administrator Update

Executive Summary

Incyte taps former Novartis Oncology president Herve Hoppenot for president and CEO role, while USP names Ron Piervincenzi CEO; Former CMS Administrator Kerry Weems joins medical supply distributor TwinMed LLC as CEO; more personnel announcements in this month’s column.

You may also be interested in...



Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs

Jesse Goodman will become director of Georgetown University’s new Center on Medical Product Access, Safety and Stewardship while Stephen Ostroff steps up as FDA’s Acting Chief Scientist.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Latest News
See All
UsernamePublicRestriction

Register

PS055902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel